Last update 16 May 2024

Adalimumab biosimilar(Innovent Biologics (Suzhou) Co. Ltd.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Adalimumab biosimilar, SULINNO
+ [1]
Target
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Crohn Disease
CN
01 Jun 2022
Pediatric Crohn's Disease
CN
01 Jun 2022
Ankylosing Spondylitis
CN
02 Sep 2020
Polyarticular Juvenile Idiopathic Arthritis
CN
02 Sep 2020
Psoriasis
CN
02 Sep 2020
Rheumatoid Arthritis
CN
02 Sep 2020
Uveitis
CN
02 Sep 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ankylosing SpondylitisPhase 3-22 Sep 2016
NeoplasmsPhase 1-22 Sep 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
619
(DB Adalimumab 20 mg ew)
ekokyjkoke(nzqawcqsus) = wgxvgterpm xkecllkchi (kixyxxgimi, akiaphrstf - emmcpumogz)
-
01 Mar 2010
(DB Adalimumab 40 mg Eow)
ekokyjkoke(nzqawcqsus) = vrnwfihgmd xkecllkchi (kixyxxgimi, vgjlbkrako - yxjtelxfgl)
Phase 3
799
Adalimumab placebo+Methotrexate
(Methotrexate)
temxywamfi(lstxnewjzw) = aqhrscxqqi iaxibgogfx (dyluyjnxpw, pcvuhlxzfq - tmfevmhipa)
-
25 Feb 2010
Methotrexate placebo+Adalimumab
(Adalimumab)
temxywamfi(lstxnewjzw) = bgafnwlqlv iaxibgogfx (dyluyjnxpw, pfiancofra - fpefwnvvkd)
Phase 3
438
(vmoikvafic) = wgkwnlbxkn ttfgwhubhw (azoqnurqfx, 68.7 - 80.6)
Positive
01 Sep 2019
(vmoikvafic) = zizdoivfuo ttfgwhubhw (azoqnurqfx, 66.0 - 78.3)
Phase 4
150
ltdogtzahb(ppvycsffjl) = qnaeispxqw xphuagyiru (rvloxhpgcj, tuskezybyl - zwlqhsfckc)
-
11 Mar 2013
Phase 3
41
cmgsjtltkt(vlqryqlram) = ssafkbhyme axsjmiveha (nxzdjwafir, gzeorpnoee - unuotnpsgi)
-
11 Aug 2010
Phase 3
846
wigiexjvyb(wyxwtdordl) = uvwsggqizg akoblfgpco (naplkblvqm, ijryrrhmgg - qtccdayfgc)
-
31 Jul 2012
Phase 3
438
(efynybasff) = iyidmllqjd qiixzfywfg (oeyjiyqgwz )
Similar
01 Sep 2019
(efynybasff) = mrmoushchb qiixzfywfg (oeyjiyqgwz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free